Equity Analysis /
United States of America

US : InflaRx N.V. - IFRX | Phase 3 Global COVID-19 Study Misses Stat Sig But Beats Our Expectations

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    31 March 2022
    Published by